Payment overview · 2025
General Payments
$378.16
22 reported records · 7 companies
Healthcare provider profile · identity verified
Arvind K Doshi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTH PLAINFIELD, NJ · NPI 1457302259
Verified facts
What the public records show
CMS Open Payments records show Arvind K Doshi, M.D. received $378.16 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $154.74 | 40.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.40 | 18.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.65 | 16.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.45 | 13.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.61 | 4.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.31 | 4.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.00 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $378.16 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $108.02 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.40 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.40 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $63.65 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.46 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1233 | 375 |
| Amlodipine Besylate | Amlodipine Besylate | 743 | 219 |
| Metoprolol Succinate | Metoprolol Succinate | 488 | 145 |
| Metformin Hcl Er | Metformin Hcl | 379 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 119 |
| Diclofenac Sodium | Diclofenac Sodium | 322 | 104 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 272 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 259 | 89 |
| Irbesartan | Irbesartan | 249 | 76 |
| Losartan Potassium | Losartan Potassium | 244 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 237 | 75 |
| Famotidine | Famotidine | 224 | 83 |
| Metformin Hcl | Metformin Hcl | 221 | 82 |
| Tradjenta | Linagliptin | 200 | 46 |
| Omeprazole | Omeprazole | 190 | 61 |
| Gabapentin | Gabapentin | 183 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 61 |
| Hydralazine Hcl | Hydralazine Hcl | 175 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 61 |
| Furosemide | Furosemide | 132 | 57 |
| Finasteride | Finasteride | 127 | 35 |
| Januvia | Sitagliptin Phosphate | 110 | 25 |
| Montelukast Sodium | Montelukast Sodium | 103 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 102 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 33 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 95 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 93 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 30 |
| Atenolol | Atenolol | 84 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 27 |
| Eliquis | Apixaban | 77 | 19 |
| Repaglinide | Repaglinide | 76 | 26 |
| Cefuroxime | Cefuroxime Axetil | 71 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 43 |
| Ezetimibe | Ezetimibe | 62 | 24 |
| Glimepiride | Glimepiride | 57 | 17 |
| Spironolactone | Spironolactone | 55 | 17 |
| Ammonium Lactate | Ammonium Lactate | 54 | 27 |
| Linzess | Linaclotide | 54 | 18 |
| Valsartan | Valsartan | 51 | 17 |
| Carvedilol | Carvedilol | 49 | 15 |
| Trazodone Hcl | Trazodone Hcl | 47 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 13 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Lactulose | Lactulose | 29 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Hydrocortisone | Hydrocortisone | 28 | 15 |
| Lisinopril | Lisinopril | 28 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 20 |
| Dutasteride | Dutasteride | 27 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 16 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | 11 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | 11 |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $378.16 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, GEMTESA, MOUNJARO, OTEZLA, Ozempic, REPATHA, VOQUEZNA, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Sumitomo Pharma America, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error